Boardroom Media (CFO News)
At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Boston based CFO’ operating in the Pharmaceutical space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Sravan K. Emany
SVP & Chief Financial Officer of Ironwood Pharmaceuticals
Sravan K. Emany is Chief Financial Officer at Ironwood. Before joining the company in 2021, Mr. Emany served as the Corporate Vice President, Commercial Excellence and Chief Strategy Officer at Integra Lifesciences Holdings Corporation, where he was responsible for the Company’s commercial support functions and led the development of their corporate strategy. Prior to Integra, Mr. Emany was at Bank of America for ten years and held roles of increasing responsibility within the Mergers & Acquisitions (M&A) business, ultimately serving as a Managing Director of the M&A group. Mr. Emany began his career working at several well-respected banking institutions including Morgan Stanley and Goldman Sachs. Mr. Emany has a B.A. in international relations and an M.A. in international relations and international economics, both from Johns Hopkins University.
Follow Sravan K. Emany:
About Ironwood Pharmaceuticals: Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.
Ommer Chohan
Chief Financial Officer of Atlas Venture
Ommer Chohan joined Atlas in 2015 and servers as the firm’s Chief Financial Officer. He oversees the firm’s financial, legal, and operations functions. Prior to joining Atlas, Ommer was CFO/COO at Summerhill Venture Partners. Ommer joined Summerhill in 2006 and was part of the original team that spun out the firm from Bell Canada. At Summerhill Ommer was responsible for the finance, IT, and administrative functions in addition to providing financial and legal support to the investment team. Prior to Summerhill, Ommer was the VP-Finance at First Asset Management Inc. (acquired by Affiliated Managers Group), a holding company with equity interests in several leading Canadian asset management firms. Ommer received his BA-Honours, Specialist in Management from the University of Toronto, his MBA from the Johnson School at Cornell University, and earned his CPA (Ontario) while at PricewaterhouseCoopers.
Follow Ommer Chohan:
About Atlas Venture: Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.
David Neafus
CFO of Santi Therapeutics
David Neafus is the CFO of Santi Therapeutics.
Follow David Neafus:
About Be the Partner, Galenea, IlluminOss Medical, Intrinsic Therapeutics, PanGenX, Santi Therapeutics, Triton Resources, Wingu: Santi Therapeutics is a pharmaceutical company that focuses on the research and development of small molecule therapeutics.
David Socks
Co-founder, CFO, and CBO of HilleVax
Follow David Socks:
About HilleVax, Phathom Pharmaceuticals: HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.
Steve Maiocco
Chief Financial Officer of Schooner Capital
Steve has been Schooner’s Chief Financial Officer since 1996. A Managing Director, Steve divides his time between Schooner’s internal financial and administrative matters and Schooner’s investment portfolio, including serving as a board member of Millstone Medical Outsourcing and Iron Rail Group. Prior to joining Schooner, Steve spent approximately fourteen years in public accounting at Tonneson & Company CPAs P.C. where he worked with his clients on a wide range of accounting, financial and tax matters. Steve has an undergraduate degree from Cornell University and a Master’s of Science in Taxation degree from Bentley University. He is also licensed as a Certified Public Accountant in the Commonwealth of Massachusetts.
Follow Steve Maiocco:
About Schooner Capital: Schooner Capital is a Boston-based private investment firm engaged in venture capital, growth equity, and public securities.
Jeff Poulton
Chief Financial Officer of Alnylam Pharmaceuticals
Follow Jeff Poulton:
About Alnylam Pharmaceuticals: Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Michael A. Doyle
Chief Financial Officer of Quanterix
With nearly 30 years of financial and management experience at major companies, Michael serves as Forrester’s chief financial officer (CFO). He leads Forrester’s finance team and oversees the company’s relationships with investors, market analysts, accountants, and bankers. Michael’s responsibilities also include both managing day-to-day financial activity as well as planning for Forrester’s long-term opportunities. Prior to joining Forrester, Michael was CFO of EasyLink Services, a publicly traded global telecommunications messaging provider. There he led an organization focused on improving productivity and financial planning and reporting. Previously, Michael served as CFO at Dun & Bradstreet, North America, responsible for driving the cash flow process improvement to record cash performance, and successfully integrating the Hoovers acquisition. Michael began his career at Continental Can where his tenure included financial management roles at the leading diversified packaging manufacturer. For the next 14 years, he held senior financial management positions at Cendant, Allied Signal, PepsiCo, as well as marketing and strategy positions at Cendant and PepsiCo. Michael holds a Master of Business Administration from New York University and a Bachelor of Business Administration in finance from the University of Notre Dame.
Follow Michael A. Doyle:
About Quanterix: Quanterix is a platform for single molecule analysis that supports clinical diagnostics, drug development, and life science researches.
Hunter Smith
Chief Financial Officer of Rhythm Pharmaceuticals
Hunter Smith is the Chief Financial Officer at Rhythm Pharmaceuticals.
Follow Hunter Smith:
About Rhythm Pharmaceuticals: Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
Bruce Tiedemann
Partner / CFO of Boston Millennia Partners
Bruce is a founder of Tiedemann & Company, an independent certified public accounting firm. He has also served as part-time Chief Financial Officer or Controller of several start-up venture funded companies. His professional experience includes over 20 years of public accounting experience.
Follow Bruce Tiedemann:
About Boston Millennia Partners: Boston Millennia Partners provides private equity financing to high growth companies in the healthcare and business services industries.
Chip Catlin
Senior Vice President and Chief Financial Officer of Celldex Therapeutics
Chip Catlin joined our board of directors in September 2018. He currently serves on the Board of Corbus Pharmaceutical Holdings, Inc. Chip Catlin previously served as Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc., where he raised more than $500 million from equity, convertible debt and private placement transactions, as well as devised and led financial strategies to successfully complete several asset acquisitions adding substantial long term value for the company. Prior to Celldex, Chip Catlin held senior financial and operational positions with biopharma companies Endogen, Inc. and Repligen Corporation. Chip Catlin earned a B.A. in Psychology from the University of Virginia and an MBA from Babson College. He is also a certified public accountant. Chip Catlin’s more than 22 years of experience as a senior financial officer of public biopharmaceutical companies make him an ideal addition to our board of directors.
Follow Chip Catlin:
About Celldex Therapeutics: Celldex is a clinical stage company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases.
Marc Schneebaum
Chief Financial Officer of Avalyn Pharma
Follow Marc Schneebaum:
About Avalyn Pharma: Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis.
Ted Myles
Executive Vice President and Chief Financial Officer of AMAG Pharmaceuticals
Ted Myles joined ACT in June 2013, as the company’s Chief Financial Officer and Executive Vice President of Corporate Development. From November 2008 to June 2013 Ted Myles was with PrimeraDx, a privately-held molecular diagnostics company, where he served as Chief Financial Officer and Vice President of Operations. At PrimeraDx, Ted Myles helped to lead the company from the proof-of-concept stage to become a fully integrated commercial organization. Prior to joining PrimeraDx, Ted Myles was the Chief Financial Officer and Senior Vice President of Finance at Pressure BioSciences, a Nasdaq-listed, life-science tools company. Earlier in his career, Ted Myles held financial positions of increasing responsibility with EMD Pharmaceuticals (a subsidiary of Merck KGaA), SG Cowen Securities Corporation, Boston Biomedica and PriceWaterhouseCoopers. He received a master’s degree in business administration, with an emphasis on strategy and corporate finance, from Washington University in St. Louis and a bachelor’s degree in business administration from the University of Hartford. Ted Myles became a CPA in 1996.
Follow Ted Myles:
About AMAG Pharmaceuticals: AMAG Pharmaceuticals is a biopharmaceutical company, which utilizes the technology for the development and commercialization of therapeutic.
Ola Soderquist
CFO/Controller & Co-founder of Oxygen Therapy
Follow Ola Soderquist:
About Oxygen Therapy: Oxygen Therapy is a biopharma company that develops anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia.
